{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:47:22Z","timestamp":1763142442931,"version":"3.44.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Takeda Pharma Gmbh"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,25]]},"abstract":"<jats:p>Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) often shows incomplete responses and progression despite tyrosine kinase inhibitor (TKI) therapy. Preliminary data suggest that combining brigatinib, an ALK-selective TKI, with surgery or radiotherapy may improve outcomes. We retrospectively analyzed patients with advanced ALK-positive NSCLC who received brigatinib as first-line treatment combined with local therapy to assess safety and efficacy of this approach in a real-world setting. Among 9 patients, 6 (67%) had stage III and 3 (33%) had stage IV adenocarcinoma. Five patients received surgery, 3 received radiotherapy, and 1 received both. Brigatinib-related adverse events (AEs) occurred in 78% of patients, primarily mild (grade\u2005\u2264\u20052). Severe AEs (grade\u2005\u2265\u20053) were seen in 22% of patients and included dyspnea and hypertension. Brigatinib was discontinued in 22% of patients due to toxicity. Local therapy-related AEs were mostly grade 1. The objective response rate was 89%, with 2 complete and 6 partial responses. At data cutoff, brigatinib was ongoing in 55% of patients, with a median treatment duration of 14 months and a 2-year progression-free survival rate of 100%. Combining brigatinib with local therapy appears safe and potentially more effective for advanced ALK-positive NSCLC. Further studies are warranted.<\/jats:p>","DOI":"10.1097\/md.0000000000042297","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T23:00:08Z","timestamp":1745881208000},"page":"e42297","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Multidisciplinary treatment of advanced or metastatic ALK-positive non-small cell lung cancer: Real-world data on Brigatinib combined with local therapy"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7322-7092","authenticated-orcid":false,"given":"Oliver","family":"Illini","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Clinic Floridsdorf, Vienna Healthcare Group, Vienna, Austria"},{"name":"Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Clinic Floridsdorf, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Fabikan","sequence":"additional","affiliation":[{"name":"Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Clinic Floridsdorf, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Breitenecker","sequence":"additional","affiliation":[{"name":"Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Clinic Floridsdorf, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Sophie","family":"Lang-St\u00f6berl","sequence":"additional","affiliation":[{"name":"Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Clinic Floridsdorf, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Krainer","sequence":"additional","affiliation":[{"name":"Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Clinic Floridsdorf, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Krenbek","sequence":"additional","affiliation":[{"name":"Department of Pathology, Clinic Floridsdorf, Vienna Healthcare Group, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Weinlinger","sequence":"additional","affiliation":[{"name":"Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Clinic Floridsdorf, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Watzka","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Clinic Floridsdorf, Vienna Healthcare Group, Vienna, Austria"},{"name":"Karl Landsteiner Institute for Clinical and Translational Thoracic Surgical Research, Clinic Floridsdorf, Vienna, Austria"},{"name":"Paracelsus Medical University, Salzburg, Austria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arschang","family":"Valipour","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Clinic Floridsdorf, Vienna Healthcare Group, Vienna, Austria"},{"name":"Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Clinic Floridsdorf, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian J.","family":"Hochmair","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Clinic Floridsdorf, Vienna Healthcare Group, Vienna, Austria"},{"name":"Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Clinic Floridsdorf, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250904","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20250904","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1158\/1078-0432.CCR-14-2748","article-title":"Lung cancer in the era of precision medicine.","volume":"21","author":"Politi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R3-20250904","first-page":"7","article-title":"Cancer statistics, 2022.","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"R4-20250904","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non\u2013small-cell lung cancer.","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"key":"R5-20250904","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.3390\/cancers14194765","article-title":"The landscape of ALK-rearranged non-small cell lung cancer: a comprehensive review of clinicopathologic, genomic characteristics, and therapeutic perspectives.","volume":"14","author":"Cognigni","year":"2022","journal-title":"Cancers"},{"key":"R6-20250904","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer.","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"R7-20250904","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"key":"R8-20250904","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor\u2013naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial.","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R9-20250904","first-page":"JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non\u2013small cell lung cancer: 5-year outcomes from the phase III CROWN study.","volume":"0","author":"Solomon","year":"2024","journal-title":"JCO"},{"key":"R10-20250904","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","article-title":"Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase\u2013positive non\u2013small-cell lung cancer: a randomized, multicenter phase II trial.","volume":"35","author":"Kim","year":"2017","journal-title":"JCO"},{"key":"R11-20250904","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nm.4091","article-title":"A framework for understanding and targeting residual disease in oncogene-driven solid cancers.","volume":"22","author":"Bivona","year":"2016","journal-title":"Nat Med"},{"key":"R12-20250904","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.jtho.2023.09.109","article-title":"OA22.04 BRIGHTSTAR local consolidative therapy with brigatinib in tyrosine kinase inhibitor-na\u00efve ALK-rearranged metastatic NSCLC.","volume":"18","author":"Elamin","year":"2023","journal-title":"J Thorac Oncol"},{"key":"R13-20250904","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"R14-20250904","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification.","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R15-20250904","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","article-title":"The eighth edition lung cancer stage classification.","volume":"151","author":"Detterbeck","year":"2017","journal-title":"Chest"},{"key":"R17-20250904","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer.","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"R18-20250904","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer.","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"R19-20250904","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ijrobp.2013.11.010","article-title":"Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.","volume":"88","author":"Gan","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15_suppl","key":"R20-20250904","doi-asserted-by":"crossref","first-page":"9624","DOI":"10.1200\/JCO.2020.38.15_suppl.9624","article-title":"BRIGHTSTAR: a pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-na\u00efve ALK-rearranged advanced NSCLC.","volume":"38","author":"Elamin","year":"2020","journal-title":"JCO"},{"key":"R21-20250904","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer.","volume":"115","author":"Wang","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"R22-20250904","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.2217\/fon-2021-0549","article-title":"Neoadjuvant osimertinib with\/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA.","volume":"17","author":"Tsuboi","year":"2021","journal-title":"Future Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042297","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T12:04:08Z","timestamp":1756987448000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":21,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042297","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2025,4,25]]}}}